Literature DB >> 35770461

Generalized and persistent skin pigmentation after COVID-19 vaccination.

J Lu1, Y Liu1, Y Sun1.   

Abstract

Entities:  

Year:  2022        PMID: 35770461      PMCID: PMC9350018          DOI: 10.1111/jdv.18379

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


× No keyword cloud information.
With COVID‐19 vaccines becoming widely available, numerous cutaneous adverse reaction patterns following vaccine injection have been increasingly reported. Most of those cutaneous reactions are self‐limited with proper treatment. Here, we report a case of generalized skin pigmentation following the first of COVID‐19‐inactivated vaccination and persistent for more than 1 year. A 27‐year‐old woman, without any history of skin disease and significant past medication, presented to our clinic with a 5‐week history of multiple brown patches on her body. The lesions appeared 1 week after the first dose of the CoronaVac‐inactivated vaccine (Sinovac). The patient mentioned that dark brown patches initially appeared on the trunk, and the lesion gradually extended to the whole body after a few days. Clinical examination revealed that dense multiple dark brown macules and patches throughout her neck,trunk and proximal extremities with 70% of body surface area involved (Fig. 1). There was no oral or genital mucosal involvement. Laboratory tests showed no significant abnormalities. Histopathological examination showed epidermal hyperpigmentation lymphocytes and perivascular infiltrate of lymphocytes with melanophores in the dermis (Fig. 2). She was administrated oral methotrexate 12.5 mg per week for 3 months. No significant improvement was observed and she denied further treatment.
Figure 1

Dark brown patch on the proximal extremities.

Figure 2

(a) Histopathological section of skin lesion demonstrating epidermal hyperpigmentation. (H&E, ×100); (b) Higher magnification demonstrates melanophores, lymphocytic perivascular infiltrate in the upper dermis. (H&E, ×400).

Dark brown patch on the proximal extremities. (a) Histopathological section of skin lesion demonstrating epidermal hyperpigmentation. (H&E, ×100); (b) Higher magnification demonstrates melanophores, lymphocytic perivascular infiltrate in the upper dermis. (H&E, ×400). Generalized pigmentation with COVID‐19 vaccination has not been reported yet. Only three cases associated with local postinflammatory pigmentation after specific primary lesions were reported with mRNA vaccination. , , Drug‐induced pigmentation accounts for up to 20% of all cases of acquired pigmentation, which is commonly associated with Non‐steroidal anti‐inflammatory drugs, tetracyclines, amiodarone, cytotoxic drugs, heavy metals and psychotropic drugs. , , The pathogenesis of drug‐induced pigmentation is unclear. Previous studies had raised several mechanistic investigations on the epidermal melanocytes overproducing melanin, synthesis of new pigment as well as deposits of iron following damage to the dermal vessel. , To our knowledge this is the first report of presenting onset generalized and persistent skin pigmentation following COVID‐19 vaccination,and clinicians need to be aware of this possible cutaneous adverse effects related to COVID‐19 vaccination.

Conflicts of interest

The authors have no conflict of interest.

Funding source

This work was funded by Taishan Scholars Program of Shandong Province (tsqn201909141) and Shandong Provincial Youth Science and Technology Talents Support Plan (ZR2020YQ56).
  10 in total

1.  SARS-CoV-2 mRNA vaccine-associated fixed drug eruption.

Authors:  D Mintoff; D Pisani; A Betts; L Scerri
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-25       Impact factor: 6.166

Review 2.  An Update on Drug-Induced Pigmentation.

Authors:  Amanda F Nahhas; Taylor L Braunberger; Iltefat H Hamzavi
Journal:  Am J Clin Dermatol       Date:  2019-02       Impact factor: 7.403

3.  Fixed drug eruption due to ibuprofen with patch test positive on the residual lesion.

Authors:  L Sánchez-Morillas; P Rojas Pérez-Ezquerra; M L González Morales; R González-Mendiola; J J Laguna Martínez
Journal:  Allergol Immunopathol (Madr)       Date:  2012-10-01       Impact factor: 1.667

Review 4.  Drug-Induced Hyperpigmentation: Review and Case Series.

Authors:  Rosa M Giménez García; Sergio Carrasco Molina
Journal:  J Am Board Fam Med       Date:  2019 Jul-Aug       Impact factor: 2.657

Review 5.  Disorders of Hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders.

Authors:  Rebecca F Wang; Dayoung Ko; Ben J Friedman; Henry W Lim; Tasneem F Mohammad
Journal:  J Am Acad Dermatol       Date:  2022-02-10       Impact factor: 11.527

6.  Minocycline-Induced Hyperpigmentation.

Authors:  Sho Katayama; Mitsuhito Ota
Journal:  N Engl J Med       Date:  2021-12-18       Impact factor: 91.245

7.  Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination.

Authors:  K Wantavornprasert; N Noppakun; J Klaewsongkram; P Rerknimitr
Journal:  Clin Exp Dermatol       Date:  2021-10-10       Impact factor: 4.481

Review 8.  Imipramine-induced hyperpigmentation: a case report and review of the literature.

Authors:  Mark L D'Agostino; Jessica Risser; Leslie Robinson-Bostom
Journal:  J Cutan Pathol       Date:  2009-07       Impact factor: 1.587

Review 9.  Cutaneous findings following COVID-19 vaccination: review of world literature and own experience.

Authors:  T Gambichler; S Boms; L Susok; H Dickel; C Finis; N Abu Rached; M Barras; M Stücker; D Kasakovski
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-11-02       Impact factor: 9.228

10.  Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.

Authors:  Joyce Kong; Francisco Cuevas-Castillo; Mahmoud Nassar; Chi M Lei; Zarwa Idrees; William C Fix; Caroline Halverstam; Adnan Mir; Amira Elbendary; Alwin Mathew
Journal:  J Infect Public Health       Date:  2021-07-08       Impact factor: 3.718

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.